Molecule
IgE
Allergic effector immunoglobulin
- Expression change
- Elevated (local and systemic)
- Evidence level
- established
- Targeted by
- Omalizumab
Role in pathogenesis
Polyclonal IgE is produced locally within polyp tissue independent of systemic atopy. IgE activates mast cells and basophils, amplifying type 2 inflammation. S. aureus superantigens drive polyclonal IgE. Targeted by omalizumab.
Targeting drugs (1)
| Drug | Mechanism | Response rate | Line |
|---|---|---|---|
| Omalizumab | Anti-IgE monoclonal antibody | Significant NPS reduction | 1st-line biologic |